A recent study has demonstrated the ability of LTBP2 to recruit CD4+ T cells, suppress the PI3K/AKT pathway, and provide immunotherapy for PCa to impede its progression [71]. The gene discussed is AKT1; the disease is posterior cortical atrophy.